Even though small molecule apigenin was reported to inhibit MUC1-CT dimerisation in the breast cancer cell lines, the inhibitory effect was probably mediated by blocking other direct targets such as heterogeneous nuclear ribonucleoprotein A2 and the oncogenic signalling pathways [34–36]. This evidence concerns the gene MUC1 and breast cancer.